CClinicalTrials.gg
TerminatedNCT03958630Updated May 1, 2024Results posted

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

A Phase 1 interventional study of 11C-ER176 and 11C-PIB in Dementia, sponsored by National Institute of Mental Health (NIMH). Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by National Institute of Mental Health (NIMH) · Phase 1, Interventional, and Diagnostic

Why this study was terminated
PI closed the protocol due to low recruitment
Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background:

Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved. Researchers want to see if scans using radioactive drugs can show brain inflammation.

Objective:

To see if the drug [11C]ER176 can show inflammation in the brain in people with certain progressive neurological disorders compared to healthy adults. Also to find genes that might be associated with or cause these disorders.

Eligibility:

People ages 18 and older with an aging-related neurological disorder, and healthy adults

Design:

Participants will be screened with a medical history, physical exam, neurological exam, psychiatric history, and blood tests.

Participants will have 2-5 visits for the first session. They will have 2 PET scans and 1 MRI scan. They may have 3 more sessions: 6 months to about 18 months later, 1 year after that, and about 30 months to 5 years after the first visit. There may be up to 20 total visits.

For the scans, participants will lie on a bed that slides into the scanners. For the PET scans, a strap will fix their head in place. A radioactive drug will be injected through a catheter. A needle will guide a thin plastic tube into an arm vein. Additional catheters may be put in place to draw blood. Each PET will take 2 hours. The MRI will take 30 60 minutes.

At each session, participants will have a brief interview, medical history, physical exam, blood and urine tests, heart tests, and memory and thinking tests. They may donate blood for DNA tests.

Read the detailed description

Objectives

The primary objective is to explore if human subjects with neurodegenerative diseases exhibit different level of neuroinflammation, as measured by brain uptake of a 3rd generation [11C]ER176 TSPO ligand, compared to control subjects. The secondary objectives are to determine, 1) if [11C]ER176 TSPO brain uptake shows disease-specific patterns across different neurodegenerative diseases and/or genetic mutations, and 2) if longitudinal imaging of individual patients shows a correlation between interval change of tracer uptake and disease progression.

Study population

Adults referred with a clinical diagnosis or with an increased risk of frontotemporal dementia, amyotrophic lateral sclerosis, Alzheimer s disease, other related adult-onset neurodegenerative disorders, or healthy control subjects.

Design

Participants will undergo a general and neurological exam, a standard battery of neuropsychological tests to measure cognitive function, blood tests for analysis of TSPO polymorphisms, MRI of the brain, and PET imaging with the [11C]ER176 TSPO radioligand and [11C]PIB amyloid radioligand. Participants will be invited to return for repeat evaluations approximately 1, 2, and 3-5 years after their initial evaluation.

Outcome measures

Brain PET and MRI scans will be co-registered for anatomic definition of regions of interest, and standard uptake value (SUV) will be calculated in various brain regions. [11C]ER176 PET data will be analyzed with compartmental modeling. [11C]PIB PET and MRI data will be adjunctly used for segregating the collected data by disease subtype. For the primary objective, we will compare TSPO radioligand uptake of healthy controls compared to subjects with neurodegenerative diseases. For secondary objectives, we will determine if neuroanatomical regions of tracer uptake differ across different neurodegenerative disease subtypes, and if interval change of tracer uptake correlates with disease progression in longitudinal imaging of individual subjects.

02

Conditions studied

  • Dementia

Keywords

  • Fronto Temporal Dementia
  • Amyloid
  • Neuroinflammation
03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's enrollment of 13 is below the median of 83 across 1,629 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

National Institute of Mental Health (NIMH) is the lead sponsor of 359 studies on the registry; 46 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 24 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Patients will be included if they
  • Are age 18 or older

    • Have the ability to understand and sign an informed consent, or have a DPA or a court-appointed guardian (or be able to understand the DPA process to appoint a DPA) to provide consent for adults without consent capacity
    • Have been given a diagnosis by a neurologist of frontotemporal dementia, frontotemporal lobar degeneration, primary progressive aphasia, semantic dementia, motor neuron disorder, amyotrophic lateral sclerosis, primary lateral sclerosis, progressive bulbar palsy, corticobasal syndrome, Huntington disease, Alzheimer s disease, or other related adult-onset neurodegenerative disease

      1. Subjects with an increased risk of neurodegenerative diseases will be included if they
    • Are age 18 or older
    • Are able to give written informed consent
    • Have known family history or other risk of an adult-onset genetic neurodegenerative disease, and/or mutation in a gene known to cause an adult-onset neurodegenerative disease

      1. Healthy subjects will be included if they
    • Are age 18 or older
    • Are willing and able to complete all study procedures
    • Are able to give written informed consent
    • Are medically healthy
    • Are enrolled in 01-M-0254 The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers (PI: Dr. Carlos Zarate) or 17-M-0181, Recruitment and Characterization of Healthy Research Volunteers for National Institute of Mental Health (NIMH) Intramural Studies (PI: Dr. Joyce Chung)

Exclusion criteria

EXCLUSION CRITERIA:

  1. Patients or subjects with an increased risk of neurodegenerative diseases will be excluded if they

    • Have other major neurological or medical diseases that may cause progressive weakness or cognitive dysfunction, such as structural brain or spinal cord disease, metabolic diseases, paraneoplastic syndromes, infectious diseases, peripheral neuropathy or radiculopathy or other significant neurological abnormalities
    • Have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., active infection or untreated malignancy)
    • Require daytime ventilator support at the time of study entry
    • Are unable to travel to NIH
    • Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits
    • Have inability to lie flat and/or lie still on camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with patient and/or caregiver during the screening visit
    • Are pregnant or breastfeeding
    • Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function
    • Are unable to have an MRI scan (e.g., pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye)
    • NIMH employees/staffs or NIH employees who are subordinates/relatives/co-workers of investigators
  2. Healthy subjects will be excluded if they

    • Have any history of medical illness or injury with the potential to affect study data interpretation or to be any medical contraindication to the procedures performed in the study, including active infection and untreated malignancy.
    • Have clinically significant laboratory abnormalities based on test performed under screening protocol 01-M-0254 or 17-M-0181
    • Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits
    • Have inability to lie flat on camera bed for at least two hours, including claustrophobia and overweight greater than the maximum for the scanner
    • Are pregnant or breastfeeding
    • Participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function
    • Are unable to have an MRI scan (e.g., pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel fragments, metal fragments in the eye)
    • NIMH employees/staffs or NIH employees who are subordinates/relatives/co-workers of investigators
05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Healthy volunteers

    Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)

    Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan

  • Experimental
    Subjects with chromosome 9 open reading frame 72 (C9ORF72)

    Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PIB followed by brain magnetic resonance imaging (MRI)

    Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan

  • Experimental
    Subjects with Frontotemporal dementia (FTD)

    Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and/or \[11C\]PiB followed by brain magnetic resonance imaging (MRI)

    Drug: 11C-ER176 · Drug: 11C-PIB · Diagnostic Test: Positron Emission Tomography (PET) Scan

Interventions

  • Drug11C-ER176

    PET biomarker for inflammation

  • Drug11C-PIB

    PET biomarker for amyloid

  • Diagnostic testPositron Emission Tomography (PET) Scan

    Participants underwent PET scan with \[11C\]ER176 and/or 11C-PIB

06

What researchers measure

Primary outcomes

  1. Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min)

    Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and standard uptake value (SUV) was measured over 90 minutes and divided by SUV of the cerebellum to determine difference of \[11C\]ER176 brain uptake

    Time frame: Up to 90 minutes during scan

07

Results

Posted May 1, 2024
Limitations and caveats
Secondary outcomes were not analyzed because: * No data for the disease specific uptake across neurodegenerative diseases * No longitudinal data was collected because the protocol was terminated due to low recruitment

Participant flow

Participant flow — Overall Study
MilestoneHealthy VolunteersSubjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)Subjects With Frontotemporal Dementia (FTD)
Started634
Completed632
Not completed002
Withdrew: Withdrawal by subject001
Withdrew: Withdrawn due to the 2019 pandemic001

Outcome measures

PrimaryStandard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min)

Participants underwent brain positron emission tomography (PET) scan with \[11C\]ER176 and standard uptake value (SUV) was measured over 90 minutes and divided by SUV of the cerebellum to determine difference of \[11C\]ER176 brain uptake

Time frame:
Up to 90 minutes during scan
Reported as:
Mean · SUV Ratio (SUVR)
Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min)
SUV Ratio (SUVR)Healthy VolunteersSubjects With Frontotemporal Dementia (FTD)Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)
Dorsolateral Prefrontal Cortex1.154816988 ± 0.10684517364601.243023793 ± 0.205605630.936561195 ± 0.190544723
Dorsomedial Prefrontal Cortex0.996700383 ± 0.0713407120.989731836 ± 0.0939287090.905523672 ± 0.048246962
Orbitofrontal Lobe1.217485758 ± 0.0884157271.267286508 ± 0.0454031151.047192088 ± 0.146706043
Perisylvian Cortex, Left1.143352336 ± 0.1021857331.132367538 ± 0.0499405321.029305407 ± 0.066022192
Perisylvian Cortex, Right1.090685411 ± 0.0712286031.112003017 ± 0.093810860.941024006 ± 0.055892402
Parietal Lobe, Left1.073048863 ± 0.0838786961.034142945 ± 0.012537280.918176888 ± 0.114668223
Parietal Lobe, Right1.020202657 ± 0.0699033261.031347183 ± 0.032119460.848570905 ± 0.190475917
Medial Temporal Lobe, Left1.08451324 ± 0.076433091.064745227 ± 0.0930634021.032603069 ± 0.036960689
Medial Temporal Lobe, Right1.080818839 ± 0.0545710411.126409887 ± 0.0379450681.006852539 ± 0.041618527
Lateral Temporal Lobe, Left1.000872064 ± 0.0951770721.009331898 ± 0.0063418760.928285311 ± 0.046290454
Lateral Temporal Lobe, Right0.970093545 ± 0.0566999040.953890974 ± 0.0222138380.868920257 ± 0.052268097
Temporal Pole, Left1.174033153 ± 0.1447181891.105735482 ± 0.0067226450.951727887 ± 0.184135923
Temporal Pole, Right1.083264223 ± 0.0896757691.133115055 ± 0.1173528420.869347972 ± 0.213594461
Occipital Lobe1.054680093 ± 0.0541343581.029642393 ± 0.0194955960.971346796 ± 0.048140098
Basal Ganglia + Thalamus1.005308052 ± 0.1201933181.000347379 ± 0.0465537250.991325953 ± 0.017050753

Adverse events

Collected over Up to 24 hours after each clinic visit for PET scan and MRI. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Volunteers0/6 (0%)0/6 (0%)0/6 (0%)
Subjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)0/3 (0%)0/3 (0%)0/3 (0%)
Subjects With Frontotemporal Dementia (FTD)0/4 (0%)0/4 (0%)0/4 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Healthy VolunteersSubjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)Subjects With Frontotemporal Dementia (FTD)Total
<=18 years0000
Between 18 and 65 years3339
>=65 years3014
Sex: Female, Male
Sex: Female, Male(Participants)Healthy VolunteersSubjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)Subjects With Frontotemporal Dementia (FTD)Total
Female52310
Male1113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Healthy VolunteersSubjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)Subjects With Frontotemporal Dementia (FTD)Total
Hispanic or Latino1001
Not Hispanic or Latino53412
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Healthy VolunteersSubjects With Chromosome 9 Open Reading Frame 72 (C9ORF72)Subjects With Frontotemporal Dementia (FTD)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White53412
More than one race0000
Unknown or Not Reported1001
08

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 31, 2021

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03958630
Lead sponsor
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
May 22, 2019
Start date
Jul 3, 2019
Primary completion
May 27, 2021
Completion
Dec 4, 2023
Results posted
May 1, 2024
Last update
May 1, 2024

Study contacts

Robert B Innis, M.D.
principal investigator · National Institute of Mental Health (NIMH)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion